Multiplexed monitoring of a novel autoantibody diagnostic signature of colorectal cancer using HaloTag technology-based electrochemical immunosensing platform

Garranzo‐Asensio, María; Guzmán-Aránguez, Ana; Povedano, Eloy; Montiel, Víctor Ruiz‐Valdepeñas; Povés, Carmen; Fernández-Aceñero, M. Jesús; Montero‐Calle, Ana; Solís‐Fernández, Guillermo; Fernández-Díez, Servando; Camps, Jordi; Arenas, Meritxell; Rodríguez-Tomàs, Elisabeth; Joven, Jorge; Sanchez-Martinez, Maricruz; Rodríguez, Núria; Domínguez, Gemma; Yáñez‐Sedeño, Paloma; Pingarrón, José M.; Campuzano, Susana; Barderas, Rodrigo

doi:10.7150/thno.42507

Cited by 24 publications

(25 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, a novel multiplexed electrochemical biosensor for the simultaneous detection of CRC-specific autoantibodies in plasma samples was developed by Garranzo-Asensio et al [48], similarly to that previously reported for a single tumor-associated antigen (TAA) (p53) [131]. The multiplexed immunosensor used HaloTag fusion proteins self-assembled on magnetic microparticles and amperometric detection at disposable SPCEs in the presence of the H 2 O 2 /HQ system ( Figure 17).…”

Section: Electrochemical Multibiosensing Of Crc-associated Biomarkersmentioning

confidence: 95%

“…Chemiluminescence tests showed that many CRC patients reacted to all TAAs. Besides, the HaloTag technology allowed covalent interaction with magnetic beads, thus improving the solubility of fusion proteins, yields, and sensitivity; and minimizing matrix effects [48]. The device is an innovative and competitive alternative for the early and reliable diagnosis of CRC.…”

Section: Electrochemical Multibiosensing Of Crc-associated Biomarkersmentioning

confidence: 99%

“…Schematic design of the strategy for the simultaneous electrochemical determination of a panel of autoantibodies composed of eight tumor-associated antigens (TAAs). Reprinted from [48] with permission. Copyright © 2020, Ivyspring International Publisher.…”

Section: Electrochemical Multibiosensing Of Crc-associated Biomarkersmentioning

confidence: 99%

Section: Current Challenges and Future Perspectives In Electrochemicamentioning

confidence: 99%

See 3 more Smart Citations

Electrochemical Biosensors for Determination of Colorectal Tumor Biomarkers

et al. 2020

View full text Add to dashboard Cite

The accurate determination of specific tumor markers associated with cancer with non-invasive or minimally invasive procedures is the most promising approach to improve the long-term survival of cancer patients and fight against the high incidence and mortality of this disease. Quantification of biomarkers at different stages of the disease can lead to an appropriate and instantaneous therapeutic action. In this context, the determination of biomarkers by electrochemical biosensors is at the forefront of cancer diagnosis research because of their unique features such as their versatility, fast response, accurate quantification, and amenability for multiplexing and miniaturization. In this review, after briefly discussing the relevant aspects and current challenges in the determination of colorectal tumor markers, it will critically summarize the development of electrochemical biosensors to date to this aim, highlighting the enormous potential of these devices to be incorporated into the clinical practice. Finally, it will focus on the remaining challenges and opportunities to bring electrochemical biosensors to the point-of-care testing.

show abstract

Section: Electrochemical Multibiosensing Of Crc-associated Biomarkersmentioning

confidence: 95%

Section: Electrochemical Multibiosensing Of Crc-associated Biomarkersmentioning

confidence: 99%

Section: Electrochemical Multibiosensing Of Crc-associated Biomarkersmentioning

confidence: 99%

Section: Current Challenges and Future Perspectives In Electrochemicamentioning

confidence: 99%

See 2 more Smart Citations

Electrochemical Biosensors for Determination of Colorectal Tumor Biomarkers

et al. 2020

View full text Add to dashboard Cite

show abstract

“…[4,14] Phage display technology, consisting of the expression of foreign peptides or proteins outside the phage virion as a fusion with one of the phage coat proteins, has demonstrated to greatly facilitate the production of novel receptors beyond known biomolecular interactions, or against toxic or non-immunogenic targets, thus providing a valuable tool in the quest of new recognition elements for biosensor development. [15] Moreover, electrochemical biosensing has demonstrated, in connection with the use of magnetic microbeads (MBs) and HaloTag technologies, its usefulness to improve the clinical potential of specific AAbs signatures against tumor-associated antigens (TAAs) in circulation, [16,17] or from exosomes released from colorectal cancer (CRC) cell lines and tissue samples from CRC patients. [18] This methodology allowed the early and differential diagnosis of patients with premalignant lesions and CRC or other prevalent neoplasias, such as lung and breast cancers.…”

mentioning

confidence: 99%

Phage‐Derived and Aberrant HaloTag Peptides Immobilized on Magnetic Microbeads for Amperometric Biosensing of Serum Autoantibodies and Alzheimer's Disease Diagnosis

et al. 2021

Self Cite

View full text Add to dashboard Cite

An electrochemical biosensing platform for serum autoantibodies (AAbs) detection is reported in this work, exploiting for the first time six Alzheimer's disease (AD)-specific phage-derived and frameshift aberrant HaloTag peptides as receptors, immobilized on magnetic microbeads (MBs) surface and captured on disposable electrodes to perform amperometric detection. Operational analytical characteristics and clinical diagnostic ability of the bioplatform were probed in optimized key experimental conditions by analysing serum AAbs of AD patients and healthy subjects. The value of 100 % obtained for AUC, sensitivity, and selectivity from the all peptides combined ROC curve, indicate full AD-diagnostic capability of the methodology, which was further implemented, as proof of concept, in a POC multiplexing platform to detect the signature in a single test over clinically actionable times (1 h 15 min), opening great promise for the type of diagnosis and AD patients' monitoring follow-up currently pursued.Alzheimer's disease (AD) is the most common form of dementia in elderly age groups worldwide, with an estimated prevalence of 10-30 % and an average duration of about 10 years since the first clinical symptoms. [1,2] However, AD has long preclinical and prodromal stages which extend the disease for up to 20 years.

show abstract

A protein microarray‐based serum proteomic investigation reveals distinct autoantibody signature in colorectal cancer

Barpanda

Tuckley

Ray

et al. 2022

Proteomics Clinical Apps

View full text Add to dashboard Cite

Purpose Colorectal cancer (CRC) has been reported as the second leading cause of cancer death worldwide. The 5‐year annual survival is around 50%, mainly due to late diagnosis, striking necessity for early detection. This study aims to identify autoantibody in patients’ sera for early screening of cancer. Experimental Design The study used a high‐density human proteome array with approximately 17,000 recombinant proteins. Screening of sera from healthy individuals, CRC from Indian origin, and CRC from middle‐east Asia origin were performed. Bio‐statistical analysis was performed to identify significant autoantibodies altered. Pathway analysis was performed to explore the underlying mechanism of the disease. Results The comprehensive proteomic analysis revealed dysregulation of 15 panels of proteins including CORO7, KCNAB1, WRAP53, NDUFS6, KRT30, and COLGALT2. Further biological pathway analysis for the top dysregulated autoantigenic proteins revealed perturbation in important biological pathways such as ECM degradation and cytoskeletal remodeling etc. Conclusions and Clinical Relevance The generation of an autoimmune response against cancer‐linked pathways could be linked to the screening of the disease. The process of immune surveillance can be detected at an early stage of cancer. Moreover, AAbs can be easily extracted from blood serum through the least invasive test for disease screening.

show abstract

Multiplexed monitoring of a novel autoantibody diagnostic signature of colorectal cancer using HaloTag technology-based electrochemical immunosensing platform

Cited by 24 publications

References 50 publications

Electrochemical Biosensors for Determination of Colorectal Tumor Biomarkers

Electrochemical Biosensors for Determination of Colorectal Tumor Biomarkers

Phage‐Derived and Aberrant HaloTag Peptides Immobilized on Magnetic Microbeads for Amperometric Biosensing of Serum Autoantibodies and Alzheimer's Disease Diagnosis

A protein microarray‐based serum proteomic investigation reveals distinct autoantibody signature in colorectal cancer

Contact Info

Product

Resources

About